Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use.

Aurelien Delluc; Elisabeth Pasquier; Luc de Saint Martin; Dominique Mottier

Journal articles

Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use.

Aurelien Delluc ^{1, 2, *} Elisabeth Pasquier ^{1, 2} Luc de Saint Martin ^{1, 2} Dominique Mottier ¹

* Corresponding author

1 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale

2 DMIP - Brest - Département de Médecine Interne et Pneumologie [Brest]

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Human health and pathology

Complete list of metadata

https://hal.univ-brest.fr/hal-00689153
Contributor : Ghislaine Calvez Connect in order to contact the contributor
Submitted on : Thursday, April 19, 2012 - 1:40:29 PM
Last modification on : Thursday, March 31, 2022 - 11:00:02 AM

Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use.

Identifiers

Collections

Citation

Export

Metrics

24

Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use.

Identifiers

Collections

Citation

Export

Share

Metrics

24